In a CNBC Pro exclusive interview from JPMorgan's Annual Healthcare Conference in San Francisco, Prothena CEO Dale Schenk gave a revealing update on the state of the company's pipeline and its prospects.
Prothena is a late-stage biotechnology company focused on the discovery and development of protein immunotherapies for diseases such as Parkinson's.
Apart from describing where promising developments are taking place, Schenk shared his views on the company's capitalization and the volatility in the biotech stock market.
Can't see the video? Here's how to become a CNBC Pro subscriber.